RU2535992C2 - Биспецифические связывающие агенты с межвидовой специфичностью - Google Patents

Биспецифические связывающие агенты с межвидовой специфичностью Download PDF

Info

Publication number
RU2535992C2
RU2535992C2 RU2009136913/10A RU2009136913A RU2535992C2 RU 2535992 C2 RU2535992 C2 RU 2535992C2 RU 2009136913/10 A RU2009136913/10 A RU 2009136913/10A RU 2009136913 A RU2009136913 A RU 2009136913A RU 2535992 C2 RU2535992 C2 RU 2535992C2
Authority
RU
Russia
Prior art keywords
seq
cdr
presented
region
human
Prior art date
Application number
RU2009136913/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2009136913A (ru
Inventor
Маттиас КЛИНГЕР
Тобиас Раум
Дорис РАУ
Сюзанна МАНГОЛЬД
Роман КИШЕЛЬ
Ральф ЛУТТЕРБЮЗЕ
Патрик Хоффманн
Петер КУФЕР
Original Assignee
Эмджен Рисерч (Мьюник) Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Рисерч (Мьюник) Гмбх filed Critical Эмджен Рисерч (Мьюник) Гмбх
Priority claimed from PCT/EP2008/002663 external-priority patent/WO2008119566A2/en
Publication of RU2009136913A publication Critical patent/RU2009136913A/ru
Application granted granted Critical
Publication of RU2535992C2 publication Critical patent/RU2535992C2/ru

Links

Images

Landscapes

  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2009136913/10A 2007-04-03 2008-04-03 Биспецифические связывающие агенты с межвидовой специфичностью RU2535992C2 (ru)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
EP07006988 2007-04-03
EP07006988.5 2007-04-03
EP07006990 2007-04-03
EP07006990.1 2007-04-03
US91366807P 2007-04-24 2007-04-24
US60/913,668 2007-04-24
EP07020640.4 2007-10-22
EP07020646 2007-10-22
EP07020640 2007-10-22
EP07020646.1 2007-10-22
EP07020641.2 2007-10-22
EP07020641 2007-10-22
EP08004741.8 2008-03-13
EP08004741 2008-03-13
PCT/EP2008/002663 WO2008119566A2 (en) 2007-04-03 2008-04-03 Cross-species-specific bispecific binders

Publications (2)

Publication Number Publication Date
RU2009136913A RU2009136913A (ru) 2011-06-20
RU2535992C2 true RU2535992C2 (ru) 2014-12-20

Family

ID=42582614

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009136913/10A RU2535992C2 (ru) 2007-04-03 2008-04-03 Биспецифические связывающие агенты с межвидовой специфичностью

Country Status (8)

Country Link
JP (1) JP2010524435A (enExample)
DK (1) DK2155788T3 (enExample)
ES (1) ES2390243T3 (enExample)
NZ (1) NZ580746A (enExample)
PT (1) PT2155788E (enExample)
RS (1) RS52492B (enExample)
RU (1) RU2535992C2 (enExample)
SI (1) SI2155788T1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109456410B (zh) * 2007-04-03 2022-01-28 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
US20100183615A1 (en) * 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
US20130273055A1 (en) * 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US9587021B2 (en) * 2011-05-21 2017-03-07 Macrogenics, Inc. CD3-binding molecules capable of binding to human and non-human CD3
MX379030B (es) 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
RU2016151235A (ru) * 2014-05-28 2018-06-28 Ф. Хоффманн-Ля Рош Аг Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус
WO2016014974A2 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016016415A1 (en) * 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
HK1250997A1 (zh) * 2015-05-01 2019-01-18 基因泰克公司 掩蔽抗cd3抗体和使用方法
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
BR112022011357A2 (pt) 2019-12-13 2022-08-23 Genentech Inc Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
JP2022087602A (ja) * 2020-12-01 2022-06-13 株式会社バイオピーク 組換え大腸菌による有用タンパク質の生産性を向上するための培養方法
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
CN115932808B (zh) * 2022-11-04 2025-05-27 四川九洲电器集团有限责任公司 一种基于多特征融合的被动声纳智能探测方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
WO2004106383A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for epcam
WO2005118635A2 (en) * 2004-06-03 2005-12-15 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2007033230A2 (en) * 2005-09-12 2007-03-22 Novimmune S.A. Anti-cd3 antibody formulations
WO2007042261A2 (en) * 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
WO2004106383A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for epcam
WO2005118635A2 (en) * 2004-06-03 2005-12-15 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2007033230A2 (en) * 2005-09-12 2007-03-22 Novimmune S.A. Anti-cd3 antibody formulations
WO2007042261A2 (en) * 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REUSCH U. et al., "Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model." Clin Cancer Res. (2006); 12(1):183-90. SEN M. et al., "Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors." J Hematother Stem Cell Res. (2001);10(2):247-60. PORTOLES P. et al., "Monoclonal antibodies to murine CD3[epsilon] define distinct epitopes, one of which may interact with CD4 during T cell activation", J Immunology (1989); 142(12): 4169-4175. *

Also Published As

Publication number Publication date
SI2155788T1 (sl) 2012-11-30
JP2010524435A (ja) 2010-07-22
RU2009136913A (ru) 2011-06-20
NZ580746A (en) 2012-05-25
RS52492B (sr) 2013-02-28
ES2390243T3 (es) 2012-11-07
DK2155788T3 (da) 2012-10-08
PT2155788E (pt) 2012-09-25

Similar Documents

Publication Publication Date Title
US11987633B2 (en) Cross-species-specific single domain bispecific single chain antibody
US20200095319A1 (en) Cross-species-specific bispecific binders
EP2155783B1 (en) Cross-species-specific cd3-epsilon binding domain
ES2390243T3 (es) Agentes de unión biespecíficos específicos de especies cruzadas
EP4059964A1 (en) Cross-species-specific binding domain
US20230357444A1 (en) Cross-species-specific binding domain
HK40072623A (en) Cross-species-specific binding domain
HK40006433A (en) Cross-species-specific binding domain
HK1141299B (en) Cross-species-specific bispecific binders
HK1178542B (en) Cross-species-specific binding domain
HK1141300B (en) Cross-species-specific cd3-epsilon binding domain
HK1178542A (en) Cross-species-specific binding domain
BRPI0809594B1 (pt) Polipeptídeo, sequência de ácido nucléico, vetor, processo para a produção de um polipeptídeo, composição farmacêutica, kit e uso de um fragmento n-terminal do domínio extracelular de cd3? de máximo de 27 aminoácidos

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant